The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
[EN] IMMUNOMODULATORS<br/>[FR] IMMUNOMODULATEURS
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2016126646A1
公开(公告)日:2016-08-11
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Immunomodulators
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20160222060A1
公开(公告)日:2016-08-04
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.